Open this publication in new window or tab >>Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
City Clin Pathologoanat Bur, Minsk 220116, BELARUS..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS..
NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
Univ Turku, Dept Pathol, Turku 20500, Finland..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences, Urology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Barngatan 4, S-22185 Lund, Sweden..
Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Barngatan 4, S-22185 Lund, Sweden..
Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Barngatan 4, S-22185 Lund, Sweden..
Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Barngatan 4, S-22185 Lund, Sweden..
Lund Univ, Skane Univ Hosp, Dept Translat Med, Diagnost Radiol, Carl Bertil Laurells Gata 9, S-20502 Malmö, Sweden..
Lund Univ, Dept Translat Med, Canc Immunol, J Waldenstroms Gata 35, S-21428 Malmö, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
NN Alexandrov Natl Canc Ctr Belarus, Minsk 223040, BELARUS..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Barngatan 4, S-22185 Lund, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer Immunotherapy.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Immunology, Genetics and Pathology, Cancer precision medicine.
Show others...
2023 (English)In: eBioMedicine, E-ISSN 2352-3964, Vol. 88, article id 104452Article in journal (Refereed) Published
Abstract [en]
Background: Cancer immunity is based on the interaction of a multitude of cells in the spatial context of the tumour tissue. Clinically relevant immune signatures are therefore anticipated to fundamentally improve the accuracy in predicting disease progression.
Methods: Through a multiplex in situ analysis we evaluated 15 immune cell classes in 1481 tumour samples. Single-cell and bulk RNAseq data sets were used for functional analysis and validation of prognostic and predictive associations.
Findings: By combining the prognostic information of anti-tumoural CD8+ lymphocytes and tumour supportive CD68+CD163+ macrophages in colorectal cancer we generated a signature of immune activation (SIA). The prognostic impact of SIA was independent of conventional parameters and comparable with the state-of-art immune score. The SIA was also associated with patient survival in oesophageal adenocarcinoma, bladder cancer, lung adenocarcinoma and melanoma, but not in endometrial, ovarian and squamous cell lung carcinoma. We identified CD68+CD163+ macrophages as the major producers of complement C1q, which could serve as a surrogate marker of this macrophage subset. Consequently, the RNA-based version of SIA (ratio of CD8A to C1QA) was predictive for survival in independent RNAseq data sets from these six cancer types. Finally, the CD8A/C1QA mRNA ratio was also predictive for the response to checkpoint inhibitor therapy.
Interpretation: Our findings extend current concepts to procure prognostic information from the tumour immune microenvironment and provide an immune activation signature with high clinical potential in common human cancer types.
Place, publisher, year, edition, pages
Elsevier, 2023
Keywords
Tumour immunology, Macrophages, Immunoscore
National Category
Cancer and Oncology
Identifiers
urn:nbn:se:uu:diva-501100 (URN)10.1016/j.ebiom.2023.104452 (DOI)000963637000001 ()36724681 (PubMedID)2-s2.0-85147117975 (Scopus ID)
Funder
Swedish Cancer Society, CAN 2018/772Swedish Cancer Society, CAN 2019/447Swedish Cancer Society, CAN 2018/816Region UppsalaInsamlingsstiftelsen Lions Cancerforskningsfond Mellansverige Uppsala-ÖrebroErik, Karin och Gösta Selanders FoundationP.O. Zetterling Foundation
Note
Patrick Micke och Tobias Sjöblom delar sistaförfattarskapet
2023-05-032023-05-032026-04-10Bibliographically approved